Dr. Lilenbaum on the Rise of Immunotherapy in NSCLC

In Partnership With:

Rogerio C. Lilenbaum, MD, discusses the rise of immunotherapy in non–small cell lung cancer. 

Rogerio C. Lilenbaum, MD, director, Banner MD Anderson Cancer Center, discusses the rise of immunotherapy in non–small cell lung cancer (NSCLC).

The introduction of immunotherapy to the oncology space has revolutionized the treatment of patients with solid tumors and some hematologic malignancies, explains Lilenbaum.

Immunotherapy can lead to improved survival and quality of life compared with traditional therapies, says Lilenbaum.

According to Lilenbaum, the impact of immunotherapy in lung cancer is akin to that of actionable molecular alterations and targeted therapy.

However, immunotherapy has demonstrated utility in a larger percentage of patients compared with targeted therapy which is reserved for patients with particular markers, concludes Lilenbaum.

Related Videos
Amandeep Godara, MBBS
Eunice Wang, MD
Yvonne Chao, MD, PhD
Ruth M. O’Regan, MD, professor, chair, Charles Ayrault Dewey Professorship of Medicine, Department of Medicine, the University of Rochester, physician-in-chief, Strong Memorial Hospital, associate director, Education and Mentoring, the Wilmot Cancer Institute at University of Rochester,
Timothy Burns, MD, PhD, associate professor of medicine, associate program director, Research, associate program director, Hematology/Oncology Fellowship Program, Department of Medicine, Division of Hematology-Oncology, UPMC Hillman Cancer Center
Sapna Patel, BA, MD
Brian Henick, MD
R. Lor Randall, MD, FACS
Edward B. Garon, MD, MS, professor of medicine, Department of Medicine, Division of Hematology/Oncology, David Geffen School of Medicine, the University of California, Los Angeles (UCLA), UCLA Health
Matthew Brunner, MD, assistant professor, hematologic specialist, medical oncology, and palliative care, Department of Medicine, University of Wisconsin Carbone Cancer Center
Related Content